CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.

CARGO Therapeutics

Today we announced the appointment of Michael Ports, PhD, as Chief Scientific Officer. In this role at CARGO, Dr. Ports will be responsible for advancing our proprietary platform technologies and discovery-stage programs. Learn more: https://bit.ly/45QfufU

Today at the 8th CAR-TCR Summit in Boston, John Rossi, CARGO’s Vice President and Head of Translational Medicine, is presenting on strategies to deliver next generation engineered CAR T-cell therapy products to overcome resistance. John is also participating in a roundtable discussion on mechanisms of resistance and how to overcome them. Learn more here: https://lnkd.in/dn-KZVN 
#CARTCR #celltherapy #CART

Today we announced the addition of independent directors to our Board of Directors, bringing together an esteemed group of experienced life science leaders with expertise spanning finance, business operations, drug discovery and clinical development, including experts and pioneers in #CART therapies and #oncology. Learn more: https://bit.ly/47KuJIs

At CARGO, we are on a mission to advance next generation #CART therapies – and we are growing! We’re currently searching for a Medical Director to join our team. In this role, you’ll leverage your strong experience working across the clinical team to identify, influence and support priority initiatives while contributing to the leadership team and the advancement of CARGO cell therapy products. Review the job description here: https://lnkd.in/gRZYD2_3
#hiring #biotechjobs #celltherapy


Congratulations to our co-founder Crystal Mackall, MD, who was recently featured in an Endpoints News special report on 20 women reshaping biopharma for her pioneering work in the CAR T-cell therapy and oncology fields and her commitment to advocating for the next generation of women in biopharma! https://bit.ly/45qvyEz 
#CART #celltherapy #oncology

We are thrilled to participate in WuXi AppTec's BOLD: Innovation That Matters online series today! Our CEO Gina Simmons Chapman shares more about our work to advance #CART therapies for cancer during the spotlight session on the next wave of cancer therapeutics. Learn more and tune in here: https://bit.ly/43s85kM #TakingBOLDAction 

	Dec '22	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24
account payables	3.48M -	5.82M 67.15%	7.43M 27.62%	5.01M 32.53%	7.17M 43.01%	7.01M 2.26%	5.37M 23.33%
accumulated other comprehensive income loss					-279K -	-323K 15.77%	635K 296.59%
cash and cash equivalents	1.87M -	42.37M 2,163.41%	60.34M 42.42%	405.73M 572.37%	81.53M 79.91%	153.58M 88.38%	71.18M 53.66%
cash and short term investments	1.87M -	42.37M 2,163.41%	60.34M 42.42%	405.73M 572.37%	375.91M 7.35%	443.48M 17.97%	404.85M 8.71%
common stock	15K -	15K 0%	1K 93.33%	41K 4,000%	39K 4.88%	46K 17.95%	46K 0%
deferred revenue	4.65M -	8.73M 87.49%	12.40M 42.14%	12.84M 3.52%	12.29M 4.28%
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory		1.88M -
long term debt	1.09M -	978K 10.44%	300K 69.33%	26.26M 8,654.33%	26.57M 1.16%		28.44M -
long term investments						567K -
net debt	22.13M -	-38.90M 275.75%	-57.45M 47.70%	-377.19M 556.52%	-53.32M 85.86%	-125.44M 135.26%	-42.59M 66.05%
net receivables	476K -	475K 0.21%	475K 0%	1.74M 266.11%	2.42M 39.22%	2.52M 3.88%
other assets
other current assets		2.02M -				2.10M -	5.17M 145.84%
other current liabilities	17.74M -	19.79M 11.54%	31.11M 57.22%	1.03M 96.69%	1.55M 50.53%	18.77M 1,109.28%	16.13M 14.07%
other liabilities						1 -
other non current assets	783K -	4.43M 466.28%	7.02M 58.34%	4.96M 29.38%	4.95M 0.20%	4.38M 11.52%	5.22M 19.26%
other non current liabilities	250K -	106.39M 42,456.40%	150.31M 41.28%	225K 99.85%
othertotal stockholders equity	11.74M -	2.60M 77.81%	3.73M 43.36%	550.49M 14,646.61%	554.41M 0.71%	661.68M 19.35%	667.41M 0.87%
preferred stock	11K -
property plant equipment net	5.53M -	9.32M 68.53%	11.97M 28.42%	38.60M 222.35%	37.53M 2.77%	36.97M 1.49%	35.72M 3.38%
retained earnings	-47.00M -	-77.60M 65.11%	-113.07M 45.71%	-145.15M 28.37%	-180.96M 24.67%	-225.31M 24.51%	-267.21M 18.60%
short term debt	22.91M -	2.50M 89.11%	2.59M 3.85%	2.28M 12.08%	1.64M 28.14%	649K 60.35%	143K 77.97%
short term investments					294.39M -	289.90M 1.53%	333.67M 15.10%
tax assets
tax payables
total assets	10.24M -	60.50M 490.62%	82.41M 36.22%	453.04M 449.72%	422.43M 6.76%	490.01M 16.00%	450.96M 7.97%
total current assets	3.93M -	46.74M 1,090.17%	63.42M 35.68%	409.48M 545.70%	379.95M 7.21%	448.10M 17.94%	410.02M 8.50%
total current liabilities	44.14M -	28.11M 36.32%	41.13M 46.35%	21.16M 48.55%	22.65M 7.03%	26.42M 16.67%	21.64M 18.10%
total debt	24.00M -	3.47M 85.53%	2.89M 16.76%	28.54M 887.24%	28.20M 1.18%	28.14M 0.24%	28.58M 1.59%
total investments					294.39M -	290.46M 1.33%	333.67M 14.88%
total liabilities	45.48M -	135.48M 197.89%	191.75M 41.54%	47.65M 75.15%	49.22M 3.29%	53.91M 9.54%	50.08M 7.10%
total liabilities and stockholders equity	10.24M -	60.50M 490.62%	82.41M 36.22%	453.04M 449.72%	422.43M 6.76%	490.01M 16.00%	450.96M 7.97%
total non current assets	6.32M -	13.76M 117.84%	19.00M 38.06%	43.56M 129.31%	42.48M 2.48%	41.92M 1.32%	40.94M 2.33%
total non current liabilities	1.34M -	107.37M 7,900.67%	150.61M 40.28%	26.49M 82.41%	26.57M 0.30%	27.49M 3.47%	28.44M 3.46%
total stockholders equity	-35.24M -	-74.98M 112.79%	-109.33M 45.82%	405.39M 470.77%	373.21M 7.94%	436.10M 16.85%	400.88M 8.08%

CRGX

COM:CARGO-TX

CARGO Therapeutics

Last Close

15.82

21/11 21:00

Market Cap

761.31M

Beta: -

Volume Today

104.27K

Avg: -

Preview